Responsible Marijuana Sales Practices to Reduce the Risk of Selling to Intoxicated Customers

NCT06235632 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 229

Last updated 2025-12-05

No results posted yet for this study

Summary

The new recreational marijuana markets are contributing to polysubstance-impaired driving and other harms, especially when marijuana is used in combination with alcohol, by selling marijuana to obviously-intoxicated customers. In this study, the effectiveness of an intervention to reduce the risk of marijuana sales to obviously-intoxicated customers will be tested in the state-licensed recreational marijuana market in Oregon, one of the first states to ban such sales. The intervention will combine efforts by state regulators to increase deterrence of the state law prohibiting marijuana sales to obviously-intoxicated customers with training of store personnel to recognize signs of intoxication and refuse sales. It will also include testing the rate at which visibly intoxicated customers are refused alcohol at nearby establishments that sell alcohol either on-site or off-site

Conditions

  • Alcoholic Intoxication
  • Automobile Accident
  • Cannabis

Interventions

BEHAVIORAL

Policy and Training Intervention

The intervention is a combination of a policy training and access to an in-depth training program to teach marijuana vendors the skills needed to refuse intoxicated customers

BEHAVIORAL

Usual and Customary Policy and Training (UC-PT) (Control) Condition

The active control training that is already provided to marijuana vendors by the Oregon Liquor and Cannabis Commission

Sponsors & Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    collaborator NIH
  • Pacific Institute for Research and Evaluation

    collaborator OTHER
  • National Opinion Research Center

    collaborator OTHER
  • Klein Buendel, Inc.

    lead INDUSTRY

Principal Investigators

  • Gill Woodall, PhD · Klein Buendel, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-15
Primary Completion
2027-07-01
Completion
2027-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06235632 on ClinicalTrials.gov